Volume 6.23 | Jun 26

Prostate Cell News 6.23 June 26, 2015
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PCN on Twitter
 
TOP STORY
Hyperactivated FRS2α-Mediated Signaling in Prostate Cancer Cells Promotes Tumor Angiogenesis and Predicts Poor Clinical Outcome of Patients
Researchers demonstrated that overactivation and hyperactivity of fibroblast growth factor receptor substrate 2α (FRS2α), as well as overexpression of cJUN and HIF1α, were positively correlated with vessel density and progression of human prostate cancer (PCa) toward malignancy. Tumor angiogenesis in mouse PCa tissues was compromised by tissue-specific ablation of Frs2α in prostate epithelial cells. [Oncogene] Abstract
Development of Simplified and Defined Cell Culture for hPSCs - Watch Now!
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

siRNA Lipid Nanoparticle Potently Silence Clusterin and Delay Progression When Combined with Androgen Receptor Co-Targeting in Enzalutamide Resistant Prostate Cancer
Gene silencing of a luciferase reporter gene in the PC3-M-luc stable cell line was first assessed in subcutaneous and metastatic PC-3 xenograft tumors. Upon validation, the effect of lipid nanoparticle siRNA targeting clusterin in combination with androgen receptor antisense oligonucleotides was assessed in enzalutamide-resistant castration-resistant prostate cancer LNCaP in vitro and in vivo models. [Clin Cancer Res] Abstract

Dual Inhibition of Survivin and MAOA Synergistically Impairs Growth of PTEN-Negative Prostate Cancer
Researchers examined monoamine oxidase A (MAOA) expression in the prostate lobes of a conditional PTEN-deficient mouse model mirroring human prostate cancer (PCa), with or without survivin knockout. They further evaluated the combination of MAOA inhibitors and survivin suppressants on the growth, viability, migration and invasion of PCa cells. [Br J Cancer] Abstract

Enrichment of the Cancer Stem Phenotype in Sphere Cultures of Prostate Cancer Cell Lines Occurs through Activation of Developmental Pathways Mediated by the Transcriptional Regulator ΔNp63α
Researchers describe a prostasphere assay for the enrichment of CD133+ cancer stem cells in four commercial prostate cancer cell lines: 22Rv1, DU145, LNCaP, and PC3. Overexpression of CD133, as determined by flow cytometric analysis, correlated with an increased clonogenic, chemoresistant, and invasive potential in vitro. [PLoS One] Full Article

Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy
The authors characterized in vitro prostate cancer (PCa) dormancy-reactivation by inducing cells from three patient-derived xenograft lines to proliferate through tumor cell contact with each other and with bone marrow stroma. Proliferating PCa cells demonstrated tumor cell-cell contact and integrin clustering by immunofluorescence. [PLoS One] Full Article

BM-MSCs Promote Prostate Cancer Progression via the Conversion of Normal Fibroblasts to Cancer-Associated Fibroblasts
Scientists found that the recruited bone marrow derived mesenchymal stem cells (BM-MSCs) might be able to convert the normal fibroblasts to more cancer associated fibroblast (CAF)-like characteristics via alteration of secreted TGFβ-1. Addition of functional TGFβ-1 or interruption with TGFβ-1 inhibitor SB431542 led to alteration of the BM-MSCs-induced CAF conversion and influence on the prostate cell growth and invasion. [Int J Oncol] Abstract

SRD5A2 Gene Expression Inhibits Cell Migration and Invasion in Prostate Cancer Cell Line via F-Actin Reorganization
Researchers showed that exogenous SRD5A2 expression in prostate cancer cell line reduced cell migration and invasion. siRNA knockdown of the endogenous SRD5A2 mRNA in LnCAP cells was effective, it reversed the phenotype, and thus induced cell motility. [Mol Cell Biochem] Abstract

CLINICAL RESEARCH

Feasibility Study of a Randomized Controlled Trial Comparing Docetaxel Chemotherapy and Androgen Deprivation Therapy with Sequential Prostatic Biopsies from Patients with Advanced Non-Castration-Resistant Prostate Cancer
Investigators conducted a single institution Phase II open-labeled randomized study to assess the safety, tolerability, and early efficacy of docetaxel chemotherapy plus androgen deprivation therapy (ADT) vs. ADT alone for patients with advanced non–castration-resistant prostate cancer with sequential prostatic biopsies. [Urol Oncol] Abstract

Randomized Phase II Trial of Docetaxel with or without PSA-TRICOM Vaccine in Patients with Castrate-Resistant Metastatic Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E1809)
Researchers assessed the clinical efficacy of the Prostvac-VF® vaccine in patients with castration-resistant metastatic prostate cancer receiving subsequent docetaxel chemotherapy. [Hum Vaccin Immunother] Abstract

Request your FREE copy of STEMCELL Technologies' new 2015 catalog!
 
REVIEWS
Circulating Long Noncoding RNA as a Potential Target for Prostate Cancer
The authors review the literature evidence for the role of long noncoding RNA in prostate cancer, which may suggest novel strategies for its prognosis, diagnosis and clinical treatment. [Int J Mol Sci] Abstract | Download Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
 
INDUSTRY NEWS
Tokai Pharmaceuticals Announces Initiation of Phase III ARMOR3-SV Trial of Galeterone in AR-V7 Positive Metastatic Castration-Resistant Prostate Cancer
Tokai Pharmaceuticals, Inc. announced the initiation of ARMOR3-SV, Tokai’s pivotal Phase III clinical trial of galeterone in men with metastatic castration-resistant prostate cancer (mCRPC) whose tumors express the AR-V7 splice variant, which is a truncated form of the androgen receptor that has been associated with non-responsiveness to commonly-used oral therapies for mCRPC. [Tokai Pharmaceuticals, Inc. (Business Wire)] Press Release

Etubics Corporation Partners with the National Cancer Institute to Further Develop Therapeutic Cancer Vaccines
Etubics Corporation announced that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute. The parties will work together to further develop the Etubics Platform, which is employed to develop novel immunotherapeutic product candidates to treat cancer. [Etubics Corporation] Press Release

Ontario Invests in Better Health and Economic Opportunity through Support for Ontario Institute for Regenerative Medicine
A new $25 million commitment positions Ontario to be an early adopter of new treatments and technologies emerging from research and commercial developments in regenerative medicine. [Ontario Institute for Regenerative Medicine] Press Release

The Society Honors Top Researchers with Awards for Excellence
Five of Canada’s most outstanding cancer scientists received prestigious cancer research awards. The Canadian Cancer Society honored five remarkable researchers with Awards for Excellence for their tremendous contributions to progress in cancer research. [Canadian Cancer Society] Press Release

From our sponsor: Induce neural progenitor cells faster and more effectively. Watch the technical video.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 3rd Annual International Conference on Advances in Medical Research (CAMR 2015)
August 17-18, 2015
Singapore, Singapore

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW Assistant Professor- Urology (University of California, Los Angeles)

Postdoctoral Fellow- Oncology (Oregon Health & Science University)

Research Technician (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellows – Molecular Mechanisms of Prostate Cancer Progression and Therapeutic Resistance (Tulane University School of Medicine)

Postdoctoral Fellowship – Molecular Mechanisms and Translational Investigations of Advanced Prostate Cancer (Cleveland Clinic Lerner Research Institute)

Research Scientists – Tissue Biorepository and Data Resource for Prostate Cancer (NYU Langone Medical Center)

Research Assistant Professor or Instructor – Prostate Cancer (Thomas Jefferson University)

Postdoctoral Positions – Cancer, Stem Cell, and Developmental Biology (Columbia University Medical Center)

Senior Postdoctoral Position – Prostate Cancer (Institut Paoli Calmettes)

Postdoctoral Positions – Molecular Cancer Biology (University of Pennsylvania)

Postdoctoral Technician – Prostate/Breast Cancer (Baylor College of Medicine)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us